1. Chen Y, Lairson DR, Chan W, et al. Cost-effectiveness of novel agents in Medicare patients with multiple myeloma: findings from a US payer’s perspective. J Manag Care Spec Pharm. 2017;23(8):831-843.

2. NCCN guidelines. Multiple myeloma Version 3.2017. https://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf.

3. Sonneveld P, De Wit E, Philippe M. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Crit Rev Oncol Hematol. 2017;112:153-170. 

4. Facon T. Maintenance therapy for multiple myeloma in the era of novel agents. Hematology Am Soc Hematol Educ Program. 2015;2015:279-285.  

5. Lipe B, Vukas R, Mikhael J. The role of maintenance therapy in multiple myeloma. Blood Cancer J. 2016;6(10):e485.

6. Dingli D, Ailawadhi S, Bergsagel L, et al. Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc. 2017;92(4):578-598.

7. Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Brit J Haematol. 2016;175(2):252-264. 

8. Moreau P, Miguel JS, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published online April 27, 2017]. Ann Oncol.  doi:10.1093/annonc/mdx096. 

9. Dimopoulos M, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(4):1319-1331.

10. Palumbo A, Chanan-Khan A, Weisel K, at al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754-766.

11. Brioli A. First line vs delayed transplantation in myeloma: Certainties and controversies. World J Transplant. 2016;6(2):321–330.

12. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-2765.

13. Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000-2014 [published online January 20, 2017]. Leukemia. doi:10.1038/leu.2016.380.

14. Shih YCT, Xu Y, Liu L, Smieliauskas F. Rising prices of targeted oral anticancer medications and associated financial burden on medicare beneficiaries. J Clin Oncol. 2017;35(22):2482-2489.

15. Rajkumar SV, Harousseau JL. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood. 2016;128(24):2757-2764.

16. Lee C, Grigorian M, Nolan R, Binder G, Rice G. A retrospective study of direct costs associated with the use of oral oncolytic medications for the treatment of multiple myeloma. J Med Econ. 2016;19(4):397-402.

17. Olszewski A, Dusetzina S, Eaton C, Davidoff AJ, Trivedi AN. Subsidies for oral chemotherapy and use of immunomodulatory drugs among Medicare beneficiaries with myeloma [published online May 25, 2017]. J Clin Oncol. doi:10.1200/JCO.2017.72.2447.

18. Roy A, Kish J, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8(4):204-215.

19. Arikian SR, Milentijivec D, Binder G, et al. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin. 2015;31(6):1105-1115.  

20. Bloudek L, Roy A, Kish JK, et al. Estimating the economic impact of adding panobinostat to the US formulary for relapsed and/or refractory multiple myeloma: a budget impact and cost-benefit model. J Manag Care Spec Pharm. 2016;22(8):991-1002.